Company Overview and News


Add 500087
to your dashboard

Headline News

Respiratory Inhaler Devices Market: Global Industry Analysis and Opportunity Assessment, 2015 - 2025

2016-03-30 prnewswire
LONDON, March 30, 2016 /PRNewswire/ -- Future Market Insights offers a 10-year forecast of the global respiratory inhaler devices market between 2015 and 2025. In terms of value, the market is expected to register a CAGR of 4.3% during the projected period. This study demonstrates market dynamics and trends in all seven regions that influence the current environment and future status of the respiratory inhaler devices market over the forecast period.

Volatile within a range; Sensex and Nifty end lower

2016-03-29 indiainfoline
We encourage visitors to register on IIFL. Registering on the site is absolutely Free and offers you the following benefits.

ACORDA THERAPEUTICS INC v. MYLAN PHARMACEUTICALS INC AB

2016-03-22 caselaw.findlaw
These appeals involve two actions brought in the District of Delaware against generic drug manufacturer Mylan Pharmaceuticals Inc. One, assigned to Chief Judge Stark, was brought by brand-name drug manufacturers Acorda Therapeutics Inc. and Alkermes Pharma Ireland Ltd.; the other, assigned to Judge Sleet, was brought by brand-name drug manufacturer AstraZeneca AB. The plaintiffs brought the actions under 35 U.

Delhi HC extends relief to pharma firms in drug ban case

2016-03-21 livemint
Court restrains the govt from enforcing a ban on hundreds of drugs for another week on Monday until it has heard petitions from drugmakers challenging the order

Indian court extends relief to pharma firms in drug ban case

2016-03-21 channelnewsasia
NEW DELHI: An Indian court restrained the government from enforcing a ban on hundreds of drugs for another week on Monday until it has heard petitions from drugmakers challenging the order, a lawyer representing some of the firms said.

Delhi HC extends relief to pharma firms in drug ban case

2016-03-21 in.reuters
NEW DELHI The Delhi High Court restrained the government from enforcing a ban on hundreds of drugs for another week on Monday until it has heard petitions from drugmakers challenging the order, a lawyer representing some of the firms said.

Indian court extends relief to pharma firms in drug ban case

2016-03-21 reuters
NEW DELHI, March 21 An Indian court restrained the government from enforcing a ban on hundreds of drugs for another week on Monday until it has heard petitions from drugmakers challenging the order, a lawyer representing some of the firms said.

DCG(I) bans 344 drugs constituting fixed dose combinations, but will it hold?

2016-03-21 financialexpress
Abhijeet Das, Senior Associate, Singhania and Partners, opines that there are multiple fronts on which the aggrieved pharma companies can contest the ban

Drug ban: Wockhardt and Laborate gets interim stay from Delhi high court

2016-03-17 livemint
Government banned FDC drugs on 10 March, citing health risks; the move was based on a report by a six-member committee headed by Chandrakant Kokate

Cipla invests additional $ 3mn in US’s Chase Pharmaceuticals

2016-03-16 financialexpress
Drug firm Cipla Ltd has made an additional investment of $3 million in US-based Chase Pharmaceuticals engaged in developing novel approaches to improve treatments for Alzheimer’s disease.

Cipla invests additional $ 3mn in US’s Chase Pharmaceuticals

2016-03-16 freepressjournal.in
New Delhi: Drug firm Cipla Ltd has made an additional investment of USD 3 million in US-based Chase Pharmaceuticals engaged in developing novel approaches to improve treatments for Alzheimer’s disease.

Cipla invests additional $ 3 million in US's Chase Pharmaceuticals

2016-03-16 business-standard
Drug firm Cipla Ltd has made an additional investment of $3 million in US-based Chase Pharmaceuticals engaged in developing novel approaches to improve treatments for Alzheimer's disease. The company in May 2014 had invested $1.5 million to acquire 14.6% stake in Chase Pharmaceuticals. "Cipla (EU) Ltd, UK, a wholly-owned subsidiary of the company made an additional investment of $3 million in Chase Pharmaceuticals towards full settlement of its obligation under the agreement arrangement for investment in Chase," Cipla said in a BSE filing.

Cipla invests additional $3 mn in US’ Chase Pharmaceuticals

2016-03-16 thehindubusinessline
Drug firm Cipla Ltd has made an additional investment of $3 million in the US-based Chase Pharmaceuticals engaged in developing novel approaches to improve treatments for Alzheimer’s disease.